Abivax S.A.
Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in chronic inflammatory diseases. It is based in France and the United States and centers on advancing its lead drug candidate, obefazimod (ABX464), through late-stage clinical development.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2022–2025
Liiketoiminta
Osuus liikevaihdostaObefazimod and related development programs for inflammatory diseases.
Asiakkaat
Abivax does not sell commercial products broadly; its direct business counterparties are primarily clinical trial sites, contract research organizations, regulators, and development partners involved in advancing its drug candidates. The ultimate end customers, if approved, are patients with chronic inflammatory diseases such as ulcerative colitis. In practice, the company’s value proposition is tied to demonstrating clinical efficacy and safety that could support future pharmaceutical adoption.
CROs, investigators, labs, and manufacturers that execute the development program.
Health authorities and ethics committees that assess trial data and approvals.
The intended end users of obefazimod if the therapy reaches commercialization.
Insurers and public health systems that would reimburse treatment use after approval.
Strategia
Abivax’s strategy is centered on advancing obefazimod through late-stage clinical development in ulcerative colitis and building evidence for immune-modulating therapies in chronic inflammatory disease. The company’s competitive position depends on translating clinical data into regulatory progress and, ultimately, a differentiated therapeutic profile. It also maintains the financing and corporate infrastructure needed for a long development cycle.
Clinical readouts are the main value driver for a single-asset biotech company.
Approval pathways depend on robust efficacy, safety, and quality data.
Biotech development requires funding and operating flexibility over multiple years.
Maantiede
Abivax is headquartered in France with a U.S. presence and reports activity tied to both Europe and the United States. Its development operations are therefore exposed to transatlantic clinical, regulatory, and capital market requirements rather than a single national market. The company’s quoted listings in Paris and on Nasdaq also reflect that dual geographic footprint.
Riskit
Abivax faces the typical risks of a clinical-stage biotech company: clinical failure, regulatory delays, and uncertainty around whether trial data will be strong enough for approval. Because its value is concentrated in a small number of programs, any setback in obefazimod or its inflammatory disease pipeline could materially affect the business.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
The company depends on obefazimod progressing successfully through late-stage trials.
Kohdistuu: Lead candidate in ulcerative colitis
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
Clinical-stage companies often require repeated external capital before commercialization.
Kohdistuu: Research and development funding
- Pipeline concentrationVaikutus: KorkeaTodennäköisyys: Korkea
The company’s value is concentrated in a limited number of programs and indications.
Kohdistuu: Obefazimod and inflammatory disease pipeline
- Regulatory and approval riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Regulators may request further data on efficacy, safety, or manufacturing quality.
Kohdistuu: Phase 3 and registration pathway
Kirjanpito
Harkinnanvaraiset erätClinical-stage biotech results are heavily affected by when trial and development costs are expensed.
Vaikutus: Affects operating loss and comparability across periods
Borrowings, convertible notes, and derivatives may require valuation inputs and remeasurement.
Vaikutus: Can create non-cash volatility in income and liabilities
Management must estimate fair values and other balance sheet items with limited observable data.
Vaikutus: Can materially affect reported assets, liabilities, and expense timing
The company adopted a policy change for certain electronic payment settlements.
Vaikutus: Affects timing of liability removal and related financial statement presentation
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
AgomAb Therapeutics NV
AGMB · Biological Products, (No Diagnostic Substances)
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company based in Antwerp, Belgium, focused on developing therapies for fibro-inflammatory diseases.
Avalo Therapeutics, Inc.
AVTX · Pharmaceutical Preparations
BioLineRx Ltd.
BLRX · Pharmaceutical Preparations
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
AbbVie Inc.
ABBV · Pharmaceutical Preparations
Apimeds Pharmaceuticals US, Inc.
APUS · Pharmaceutical Preparations
Päivitetty: 28.9.2026